Incretin-based therapy for type 2 diabetes: What have we learned from the meta-analyses?

被引：0
|
作者：
Barakat, Amr F. [1 ]
Mahmoud, Ahmed N. [2 ]
Elgendy, Islam Y. [2 ]
机构：
[1] Cleveland Clin Fdn, Dept Med, 9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Univ Florida, Dept Med, Div Cardiovasc Med, Gainesville, FL USA
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2017年 / 239卷
关键词：
CONTROLLED RANDOMIZED-TRIALS; CARDIOVASCULAR SAFETY; INHIBITORS;
D O I：
10.1016/j.ijcard.2017.01.144
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：19 / 19
页数：1
相关论文
共 43 条
  • [21] Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes
    Scheen, Andre J.
    CLINICAL PHARMACOKINETICS, 2015, 54 (01) : 1 - 21
  • [22] Therapeutic molecules against type 2 diabetes: What we have and what are we expecting?
    Kumar, Ashwini
    Bharti, Sudhanshu Kumar
    Kumar, Awanish
    PHARMACOLOGICAL REPORTS, 2017, 69 (05) : 959 - 970
  • [23] Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis
    Wang, Wen
    Gao, Yun
    Chen, Dawei
    Wang, Chun
    Feng, Xiaobing
    Ran, Xingwu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 129 : 213 - 223
  • [24] Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies
    Igweokpala, Samuel
    Sule, Naheemot Olaoluwa
    Douros, Antonios
    Yu, Oriana H. Y.
    Filion, Kristian B.
    DIABETES OBESITY & METABOLISM, 2024, 26 (02) : 721 - 731
  • [25] Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction
    Russell, Sheldon
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (02) : 159 - 172
  • [26] Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
    Nauck, M.
    Smith, U.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (04) : 513 - 523
  • [27] Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis
    Chou, Che-Yi
    Chang, Ying-Tzu
    Yang, Jia-Lian
    Wang, Jiun-Yi
    Lee, Tsui-Er
    Wang, Ruey-Yun
    Hung, Chin-Chuan
    SCIENTIFIC REPORTS, 2017, 7
  • [28] The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials
    Wu, Shanshan
    Gao, Le
    Cipriani, Andrea
    Huang, Yi
    Yang, Zhirong
    Yang, Jun
    Yu, Shuqing
    Zhang, Yuan
    Chai, Sanbao
    Zhang, Zilu
    Sun, Feng
    Zhan, Siyan
    DIABETES OBESITY & METABOLISM, 2019, 21 (04) : 975 - 983
  • [29] Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors
    Willis, Michael
    Asseburg, Christian
    Neslusan, Cheryl
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 148 : 222 - 233
  • [30] Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system
    Liang, Yankun
    Zhang, Zhenpo
    Zheng, Jingping
    Wang, Yuting
    He, Jiaxin
    Zhao, Juanzhi
    Su, Ling
    ENDOCRINE CONNECTIONS, 2024, 13 (12)
12345